Abstract #0987

Multimodal quantitative MRI biomarkers: identification of the specific damage in Progressive Supranuclear Palsy versus Parkinson’s disease

Nadya Pyatigorskaya^1,2,3, Rahul Gaurav¹, Lydia Yahia-cherif¹, Claire Ewenczyk⁴, Cecile Gallea¹, Romain Valabregue¹, Fatma Gargouri¹, Eric Bardinet¹, Isabelle Arnulf^3,5, Cyril Poupon⁶, Marie Vidailhet^3,4, and Stephane Lehericy^1,2,3

¹Centre de NeuroImagerie de Recherche – CENIR, ICM, Paris, France, ²Neuroradiology department, APHP, Pitié-Salpêtrière hospital, Paris, France, ³UMR S 1127, CNRS UMR 7225, ICM, UPMC Univ Paris, Paris, France, ⁴Clinique des mouvements anormaux, Département des Maladies du Système Nerveux, Hôpital Pitié-Salpêtrière, PARIS, France, ⁵Service des pathologies du Sommeil, Hôpital Pitié-Salpêtrière, APHP, Paris, France, ⁶NeuroSpin, CEA, Gif-Sur-Yvette, France

We used quantitative multimodal MRI to investigate the region-specific damage in progressive supranuclear palsy (PSP) in order to generate a precise in-vivo model of neurodegeneration at various levels of the central nervous system. Additionally, we aimed to test the markers for differentiating the PSP from Parkinson disease (PD) patients and from healthy subjects. PSP patients showed extensive volume decrease and microstructural diffusion changes in the brainstem and the basal ganglia in agreement with previous pathological studies. These results suggest the possibility of direct non-invasive assessment of brain damage in PSP even in small brainstem nuclei.

This abstract and the presentation materials are available to members only; a login is required.

Join Here